June 2016 ARTICLE LIST >>
PharmaTutor (June- 2016)
Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 4, Issue 6)
Received On: 20/01/2016; Accepted On: 27/01/2016; Published On: 01/06/2016
AUTHORS:
Chauhan Sudhanshu*1,2, Savani Pankaj2, Solanki Divya2, Raj Hasumati2, Patel Sagar2
1Research Scholar, Gujarat Technological University, Ahmedabad, Gujarat, India
2Department of Quality Assurance,
Shree Dhanvantary Pharmacy College, Kim, Surat, Gujarat, India
* sudhanshuchauhan32@yahoo.com
ABSTRACT: This review article presents the pharmacology of combined Candesartan Cilexetil and Pioglitazone Hydrochloride therapy specially in Metabolic syndrome. Candesartan Cilexetil is a antihypertensive agent. Pioglitazone Hydrochloride is a selectively stimulates nuclear receptor peroxisome proliferator activated receptor gamma (PPAR-gamma). The use of Candesartan Cilexetil in combination with Pioglitazone Hydrochloride has been proved to provide beneficial effect (Synergistic effect) in metabolic syndrome. The mechanism of Candesartan Cilexetil and Pioglitazone Hydrochloride is quite different. The combination of both also have anti inflammatory and enhanced organ protective effects. The main objective of this review article is to provide pharmacological information of combined therapy of Candesartan Cilexetil and Pioglitazone Hydrochloride to researcher in development of combined dosage form of this combination.
How to cite this article: Chauhan S, Savani P, Solanki D, Raj H, Patel S; Review: Combined Candesartan Cilexetil and Pioglitazone Hydrochloride therapy in Metabolic Syndrome; PharmaTutor; 2016; 4(6); 23-28
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Kaur G., Mukundan S., Wani V. and Kumar M.S.; Nutraceuticals in the Management and Prevention of Metabolic Syndrome; Austin J Pharmacol Ther.; 2015; 3(1); 1063
2. Aganovic I. and Dusek T.; Pathophysiology of Metabolic Syndrome; The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine; 2007; 18(1); 1-5
3. Reilly M.P., Rader D.J.; The Metabolic Syndrome; Mini-Review: Expert Opinions; 2003; 1546-1551
4. Japanese Pharmacopeia, The Ministry of Health, Labour and Welfare, 16th Edition; Official From March 24; 2011; 511-1249
5. M.J O’Neil, P.E Heckelman, C.B Koch and K.J Roman; The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals; Fourteenth edition; Merck & Co.,Inc.; Whitehouse Station; NJ; USA; 2006; 291-1335
6. Gleiter C.H., Jagle C., Gresser U. and Morike K.; Candesartan; Cardiovascular Drug Reviews; 2004; 22(4); 263-268
7. Asif H., Sabir M.D., Mitra M. and Bhasin P.S., A review on candesartan: pharmacological and pharmaceutical profile; Journal of Applied Pharmaceutical Science; 2011; 1(10); 12-17
8. Radhika B., Vijayakumar S. and Ramaiyan D.; A pharmacokinetic interaction of pioglitazone and its clinical applications: A short review; International Journal of Pharmaceutical Sciences Letters; 2012; 2(1); 1-9
9. Kaku K., Enya K., Sugiura K. and Totsuka N.; Efficacy and Safety of combination therapy with Candesartan Cilexetil and Pioglitazone Hydrochloride in patients with hypertension and type 2 diabetes mellitus; Current Medicinal Research Opinion; 2011; 3; 73-84
10. Suzuki et al.; Effects of co-administration of Candesartan and Pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report; Cardiovascular diabetology; 2013; 12:71; 1-9
11. Jonathan C.F., Michele M. and Waldstreicher J.; Combination therapy using a dual PPAR alpha/gamma agonist and an Angiotensin ii type i receptor antagonist; United state patent; WO2004017896; 2004
12. Candesartan Drug Info in Drug bank. (Database Available On Internet), September 2015, drugbank.ca/drugs/DB00796
13. Pioglitazone Drug Info in Drug bank. (Database Available On Internet), September 2015, drugbank.ca/drugs/DB01132
14. Masae S., Yoshinori N., Muneo N. and Toshio Y.; Medicinal Composition; Japanese Patents; JP2009107944; 2009
.png)
